Alpha Tau Medical Ltd., (DRTS): Price and Financial Metrics
GET POWR RATINGS... FREE!
DRTS Stock Price Chart Interactive Chart >
DRTS Price/Volume Stats
| Current price | $4.00 | 52-week high | $20.65 |
| Prev. close | $4.06 | 52-week low | $3.75 |
| Day low | $3.97 | Volume | 37,000 |
| Day high | $4.24 | Avg. volume | 225,183 |
| 50-day MA | $4.58 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 267.89M |
Alpha Tau Medical Ltd., (DRTS) Company Bio
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest DRTS News From Around the Web
Below are the latest news stories about ALPHA TAU MEDICAL LTD that investors may wish to consider to help them evaluate DRTS as an investment opportunity.
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateJERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2022 financial results and provided a corporate update. "Alpha Tau remained active in the third quarter, as we continued preparations for our upcoming U.S. pivotal study in recurrent cutaneous squamous cell carcinoma and laid the groundwork for exploration of our Alpha DaRT |
Alpha Tau to Present at Upcoming November Investor ConferencesJERUSALEM, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will present in person at the following investor conferences in November: Event:Jefferies London Healthcare ConferenceDate & Time:Wednesday, November 16, 2022 at 4:25pm GMTLocation:London, UKEvent:Piper Sandler 34th Annual Healthcare ConferenceDate & Time:Wednesday, Novemb |
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge - - Health Canada approves the addition of Jewish General Hospital in Montreal as a second site in the Company’s clinical trial in advanced pancreatic cancer - - Dr. Christopher Barker of Memorial Sloan Kettering Cancer Center will be delivering a presentation at the ASTRO 2022 Annual Meeting regarding results of the Com |
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American Society for Radiation Oncology (ASTRO) – – Study on combinations with chemotherapy and anti-angiogenic therapy in human glioblastoma multiforme xenografts accepted for publication by Frontiers in Oncology, in its Radiation Oncology section – JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medic |
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial OfficerJERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of Directors in order to assume the full-time position of Alpha Tau’s Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical |
DRTS Price Returns
| 1-mo | -6.10% |
| 3-mo | -40.12% |
| 6-mo | -52.94% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...